AI Consensus Investment Thesis
Sanofi (SAN) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
STRONG BUY€83
+11.8%+15.1% incl. dividends5-Year
BUY€102
+38.1%+60.0% incl. dividendsLatest flagship insight
Immunology Cash Engine Offsets Approaching Exclusivity Cliff Amid Strategic Pipeline Renewal
High consensus indicates robust near-term operating cash flows driven by expanding immunology indications and specialty launches will sustain generous capital returns. However, sharp divergence persists regarding terminal valuation durability, as the looming 2031 compound patent boundary and recent clinical pipeline attrition cap sustained multiple expansion.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Universal Investor (Polymath), Machiavelli (Insider), Warren Buffett (Value Purist), J.P. Morgan (Titan), Elon Musk (Visionary), Ray Dalio (Strategist), Sherlock Holmes (Whistleblower), Superintelligence (Anthropologist), Michael Burry (Vulture). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Sanofi at the forecast anchor (2026-09-18): $16,650 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 3.0% net dividend yield for Sanofi.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in EUR; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (EUR) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 76.45 | +3.24% | +3.24% | Third-quarter results confirm robust respiratory volume expansion and launch portfolio scaling, reassuring investors following summer pipeline impairments. Systematic share buybacks absorb residual selling pressure, supporting modest multiple stabilization into year-end trading. |
| Q1 2027 | 78.96 | +3.28% | +6.63% | Full-year earnings validate double-digit operating growth, meeting upgraded guidance. Capital allocation clarity following the consumer carve-out and sustained dividend declarations provide fundamental downside protection, encouraging institutional accumulation from oversold valuation levels. |
| Q2 2027 | 80.51 | +1.97% | +8.73% | Annual dividend detachment creates typical seasonal price drag, partially cushioned by solid first-quarter operational cash flows. Specialty launch adoption across European markets continues broadening, though macro rate pressures keep multiple expansion measured. |
| Q3 2027 | 82.77 | +2.80% | +11.77% | Accelerating prescription momentum across expanded respiratory indications confirms commercial operating leverage. Portfolio pruning and manufacturing transfers progress smoothly, allowing clean operating profit expansion to offset mature brand pricing concessions in regulated markets. |
| Q4 2027 | 85.37 | +3.14% | +15.28% | Strong autumn infant RSV immunization shipments and seasonal vaccine deliveries boost fourth-quarter revenue. Ongoing float reduction from disciplined buybacks amplifies per-share earnings growth, driving steady capital appreciation into the annual close. |
| Q1 2028 | 88.24 | +3.37% | +19.17% | Fiscal results show core business operating margins widening toward twenty-eight percent as commercial scale absorbs research overhead. The board announces another progressive dividend increase, reinforcing cash generation durability despite lingering exclusivity debates. |
| Q2 2028 | 89.72 | +1.68% | +21.17% | Dividend distributions temporarily temper equity momentum, though underlying specialty care cash flows remain resilient. Rare disease therapies gain market share across North America, softening headline reimbursement headwinds from statutory healthcare price containment. |
| Q3 2028 | 91.65 | +2.15% | +23.77% | Commercial execution across non-flagship launches demonstrates genuine franchise diversification. Contribution margins improve as initial launch costs moderate, allowing steady business earnings growth to support equity value even as pipeline replacement assets remain discounted. |
| Q4 2028 | 93.65 | +2.18% | +26.47% | Peak respiratory immunization revenues provide strong seasonal cash conversion. Investors gain clearer visibility into late-stage neuroimmunology trial timelines, maintaining constructive sentiment and supporting modest multiple expansion before medium-term patent discussions intensify. |
| Q1 2029 | 96.14 | +2.66% | +29.84% | Annual disclosures confirm record free cash flow generation exceeding nine billion euros. Management emphasizes balance-sheet preservation over speculative megadeals, anchoring investor trust and delivering steady per-share accretion through ongoing share count reduction. |
| Q2 2029 | 97.59 | +1.51% | +31.80% | Annual dividend detachment and intensifying US payer rebate pressures create transient valuation friction. However, international specialty sales growth and stable gross margins above seventy percent protect underlying earnings, holding share prices steady. |
| Q3 2029 | 99.25 | +1.70% | +34.04% | Specialty therapies achieve mature commercial efficiency, allowing operating income to grow faster than top-line revenue. Prudent bolt-on licensing reinforces the development pipeline without stressing conservative leverage, driving modest defensive outperformance. |
| Q4 2029 | 101.14 | +1.90% | +36.58% | Solid third-quarter volumes across rare blood disorders and immunology sustain full-year guidance delivery. Strong operational execution offsets emerging biosimilar litigation headlines, closing the fiscal year with resilient free cash conversion. |
| Q1 2030 | 102.70 | +1.54% | +38.69% | Full-year results highlight peak flagship revenue delivery, but market attention shifts decisively toward the approaching March 2031 patent deadline. Sell-side models begin publishing post-exclusivity earnings bridges, neutralizing operational outperformance. |
| Q2 2030 | 103.17 | +0.46% | +39.32% | Substantial dividend yields and solid quarterly cash conversion anchor equity pricing during the annual distribution window. Investors demand tangible evidence of secondary formulation patent durability, keeping forward valuation multiples tightly rangebound. |
| Q3 2030 | 103.59 | +0.41% | +39.90% | Pre-expiry operating cash generation remains robust, supported by established launch cohorts and operational spending discipline. However, terminal value discounting accelerates as biosimilar competitors reveal regulatory preparation, capping further valuation progress. |
| Q4 2030 | 103.19 | -0.39% | +39.35% | Approaching patent expirations trigger tactical institutional de-risking ahead of the final exclusivity year. Reverse operating leverage concerns on fixed commercial infrastructure induce valuation multiple contraction, outweighing resilient underlying quarterly cash flows. |
| Q1 2031 | 101.39 | -1.74% | +36.93% | Primary United States compound patent expiration arrives, generating sharp headline volatility and litigation focus. Cautious analyst revisions and initial pricing uncertainty prompt controlled valuation compression, cushioned only by high dividend yields. |
| Q2 2031 | 101.10 | -0.29% | +36.53% | Post-expiration commercial disclosures show initial volume erosion remains manageable due to complex biologic manufacturing barriers and patient inertia. Generous dividend payments attract contrarian value buyers, stabilizing trading at discounted levels. |
| Q3 2031 | 102.23 | +1.12% | +38.06% | Diversified revenue streams from established rare disease, neurology, and vaccine franchises cushion initial legacy exclusivity losses. Equity pricing achieves a durable terminal equilibrium, supported by solid cash conversion and disciplined capital stewardship. |
The investment thesis rests on an asymmetric temporal mismatch: intermediate biological earning power is underpriced, yet terminal durability remains legitimately constrained. Expanding respiratory indications for the primary immunology asset and accelerating adoption of newer rare disease and pediatric immunization therapies drive high-single-digit sales growth and expanding operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry. Strong cash conversion and divestment liquidity comfortably support disciplined share repurchases and progressive dividends. Valuation sensitivity centers on whether secondary delivery patents and pipeline assets can extend cash-flow duration beyond the March 2031 compound patent boundary, or whether reverse operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry will erode terminal multiplesterminal multipleValuation metric used to estimate the value of a company beyond the explicit forecast period.View full glossary entry.
Key insights
- Divestment liquidity and high free cash conversion insulate near-term capital returnscapital returnsDistributions of capital to investors, commonly through dividends or share repurchases.View full glossary entry, providing structural downside protection even if broader macroeconomic discount rates stay elevated.
- Pruning uncompetitive Phase 3 assets protects near-term operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry and return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry, yet increases reliance on targeted external business development.
- Severe terminal valuationterminal valuationTerminal valuation is the estimated value of an asset or business beyond the explicit forecast period in a discounted cash flow model.View full glossary entry discounts already reflected in single-digit earnings multiples reduce downside asymmetry, making execution in launch diversification the primary alpha driver.
The company is generating record cash flows from its blockbuster treatments and new specialty medicines, creating a strong safety buffer for investors. While Wall Street worries about future patent expirationspatent expirationsThe end of patent protection, after which competitors may be able to offer equivalent or similar products.View full glossary entry starting in 2031, surging sales and large cash reserves from selling non-core units fund steady dividends and share buybacks. The business is trading at a bargain valuation that overlooks several years of predictable earnings growth.
Key insights
- Dependable cash generation and healthy dividends protect investors while management navigates upcoming pharmaceutical patent expirationspatent expirationsThe end of patent protection, after which competitors may be able to offer equivalent or similar products.View full glossary entry.
- Terminating weak research programs cuts wasteful spending, freeing up capital to acquire stronger medical assets.
- Discounted share prices provide a margin of safetymargin of safetyThe difference between an estimated intrinsic value and the purchase price, intended to allow for uncertainty or analytical error.View full glossary entry, meaning even modest commercial success can reward shareholders.
Deep Dive
Market consensus treats the company as a vulnerable single-blockbuster enterprise destined for sharp terminal decay once core United States patent exclusivity expires in March 2031. Sell-side research anchors heavily on historical clinical trial discontinuations, pricing the equity at a persistent single-digit multiple that discounts intermediate cash generation and treats non-flagship portfolio diversification as unproven.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Market consensus treats the company as a vulnerable single-blockbuster enterprise destined for sharp terminal decay once core United States patent exclusivity expires in March 2031. Sell-side research anchors heavily on historical clinical trial discontinuations, pricing the equity at a persistent single-digit multiple that discounts intermediate cash generation and treats non-flagship portfolio diversification as unproven.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates value, creating meaningful underpricing. The market's central blind spot is treating terminal patent risk as an immediate impairment rather than an event five years away. By capitalizing a patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry prematurely, the crowd overlooks that expanding respiratory indications and new rare disease launches generate substantial recurring cash flows before exclusivity lapses. Furthermore, the market fails to credit the capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry optionality created by substantial consumer divestment proceeds, which fund accretive share repurchases.
Repricing Catalyst
What could make the market recognize and close that gap? Consecutive quarterly earnings releases demonstrating sustained double-digit specialty care expansion and operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry leverage will force consensus multiple normalization. The trigger will be visible commercial acceleration across newly launched hemophilia and infant respiratory therapies alongside continued volume compounding in chronic obstructive pulmonary disease. As share count reductions visibly enhance per-share business earnings through the 2027 reporting cycle, institutional allocators will be compelled to close the unwarranted peer valuation discount.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- Moderate
- Cycle position
- Stabilization
Sentiment reflects broad consensus on near-term stabilization supported by robust cash conversion, yet sharp tension remains regarding terminal cycle duration. Skeptics view multiple contraction as structural due to looming patent boundaries, whereas constructive perspectives anticipate a steady cyclical recovery.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop of restrictive central-bank benchmark rates and elevated sovereign yields represents a net relative tailwind. While higher discount rates compress long-duration biotech multiples, the company's inelastic biological demand, robust gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry, and minimal financial leverage insulate it from debt refinancingdebt refinancingReplacing existing debt with new borrowing, often to change maturity, interest cost, currency, or covenants.View full glossary entry shocks, attracting defensive capital rotations seeking dependable cash yields.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary analytical disagreement across reports concerns terminal multipleterminal multipleValuation metric used to estimate the value of a company beyond the explicit forecast period.View full glossary entry behavior ahead of the March 2031 United States patent expiration. Constructive views argue that exceptional near-term cash generation, consumer divestment proceeds, and launch portfolio diversification will drive multiple rerating toward twelve to fifteen times earnings. Conversely, skeptical perspectives emphasize reverse operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry, asserting that a fixed commercial cost base facing biologic genericization justifies persistent single-digit multiples. Resolving this tension requires observing whether non-flagship launches sustain double-digit growth while secondary formulation patents survive initial judicial challenges.
Base-Case Forces
Event Risk ScoreModerate41/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Flagship respiratory indication volume compounding | Competitive Positioning | +25% | +30% | The core immunology biologic continues compounding volume across chronic obstructive pulmonary disease and newly approved respiratory indications. Surpassing five billion euros quarterly, this high-margin franchise benefits from physician prescribing inertia and entrenched market access. The resulting operational leverage expands operating earnings and funds capital returnscapital returnsDistributions of capital to investors, commonly through dividends or share repurchases.View full glossary entry through late decade, despite eventual patent boundaries; assessed likelihood is 90%. |
| Specialty launch portfolio commercial scaling | Innovation And Product | +18% | +20% | Non-flagship pharmaceutical launches, spearheaded by therapies for hemophilia A, infant respiratory syncytial virus protection, and multiple myeloma, are expanding at roughly fifty percent annually. Generating over five billion euros with gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry above eighty percent, this commercial scaling diversifies revenue streams away from single-asset reliance and steadily builds durable post-cliff earning power; assessed likelihood is 85%. |
| Divestment liquidity deployment into buybacks | Capital Allocation | +14% | +12% | Monetizing control of the consumer healthcare division crystallized approximately ten billion euros in net cash proceeds. Directing surplus liquidity into structured share repurchases at compressed valuation multiples permanently shrinks the share count. This capital returncapital returnCash or value distributed to investors, commonly through dividends, share repurchases, or return-of-capital payments.View full glossary entry mechanism mechanically accelerates per-share earnings growth and establishes a resilient valuation floorvaluation floorA price or valuation level believed to have durable support from cash flows, assets, policy, or demand.View full glossary entry against broader equity market fluctuations; assessed likelihood is 80%. |
| Operational discipline and portfolio pruning | Operational Efficiency | +11% | +14% | Executive leadership has instituted rigorous capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry by discontinuing non-differentiated clinical programs and transferring mature manufacturing sites to strategic partners. Eliminating redundant clinical expenditures and shedding low-margin legacy facilities lowers fixed operating overhead. This restructuring expands core business operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry toward thirty percent, increasing cash conversion efficiency on remaining commercial sales; assessed likelihood is 75%. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Impending compound patent exclusivity cliff | Competitive Positioning | -18% | -10% | The primary United States compound patent for the core immunology franchise expires in March 2031, with European boundaries approaching concurrently. Generating over a third of group sales, this revenue concentration causes institutional investors to discount terminal cash flows aggressively. This structural overhang persistently compresses price-to-earnings multiples, capping valuation expansion despite robust near-term volume delivery; assessed likelihood is 95%. |
| Late stage clinical research attrition | Innovation And Product | -13% | -12% | High-profile clinical discontinuations, exemplified by terminating amlitelimab in eczema alongside past regulatory setbacks in neurology, reveal ongoing internal pipeline renewal deficits. Writing off capitalized developmental expenditures forces management to sustain elevated research outlays near eighteen percent of revenue. This ongoing clinical attrition delays organic revenue replacement and reinforces investor skepticism; assessed likelihood is 90%. |
| Statutory drug pricing reimbursement containment | Regulatory | -10% | -12% | Implementation of United States Medicare drug price negotiations and tightening European statutory rebate frameworks steadily compress net realized pharmaceutical prices. As top-selling specialty therapies enter mandatory discount schedules, gross-to-net price realization erodes across key commercial lines. This regulatory drag dampens gross margin expansiongross margin expansionAn increase in gross profit as a percentage of revenue.View full glossary entry and demands higher volume throughput to maintain baseline earnings growth; assessed likelihood is 85%. |
| Macroeconomic rates and currency translation | Macroeconomic And Macrofinancial | -8.0% | -7.0% | Persistent central-bank monetary tightening maintains elevated discount rates, reducing the net present value of long-dated biopharmaceutical cash flows. Furthermore, generating over forty percent of revenue in North America while reporting in euros exposes earnings to foreign exchange volatility and cross-border trade friction. These currency translation headwinds routinely shave points off reported revenue and business earnings; assessed likelihood is 80%. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Accelerated biosimilar patent estate invalidation | 30% | -30% | Adverse court rulings or successful inter partes reviews could invalidate secondary formulation and delivery patents before 2030, enabling aggressive biosimilar entry immediately upon March 2031 compound expiration or earlier. Triggered by coordinated litigation from generic consortia, rapid formulary displacement would collapse net realized pricing by over sixty percent within two years, permanently eroding group operating profits and endangering dividend expansion; probability is 30%. |
| Severe clinical toxicity or regulatory hold | 25% | -22% | Emergence of unanticipated drug-induced liver injury or severe systemic safety signals in late-stage neurology or immunology programs could force regulatory clinical holds by 2028. Triggered by safety surveillance or pivotal trial failures, immediate asset abandonment would generate multi-billion-euro intangible impairments, eliminate key post-cliff replacement pillars, and force panic-driven, dilutive M&A that impairs balance-sheet strength and shareholder returns; probability is 25%. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Frexalimab breakthrough in multiple sclerosis | 35% | +25% | Pivotal Phase 3 clinical trials for anti-CD40L antibody frexalimab could demonstrate definitive disease progression reduction in secondary progressive multiple sclerosis by 2028. Triggered by superior neuroprotective efficacy and clean hepatic safety, regulatory approval in this underserved population would unlock over three billion euros in peak commercial sales. This clinical validation would decisively resolve post-cliff revenue succession, expanding forward valuation multiples; probability is 35%. |
| Secondary patent defense extends exclusivity | 30% | +28% | Successful legal defense of high-concentration formulations, novel autoinjector devices, and extended four-weekly dosing schedules could legally push effective commercial exclusivity in the United States beyond 2033. Triggered by favorable federal court rulings against early biosimilar challenges by 2028, this outcome would protect billions in high-margin cash flows, restoring terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry confidence and triggering aggressive multiple rerating toward global peer averages; probability is 30%. |
Company Financial Analysis
Sanofi Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Headline financial reports show sharp profit swings that conceal an underlying commercial acceleration. In fiscal 2025, revenue reached 46.7 billion euros with net income expanding to 7.81 billion euros. While second-quarter 2026 reported accounting profit dropped sharply to 343 million euros, this decline was driven by a one-off 1.03-billion-euro pipeline impairment following the termination of uncompetitive eczema studies, rather than falling medicine demand. Underneath these accounting charges, core business performance is strengthening. Driven by blockbuster immunology demand and rapid uptake of infant respiratory and hemophilia therapies, quarterly operating sales grew by double digits. Management consequently upgraded full-year 2026 constant-currency sales targets to approximately 10%.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | EUR 46.7B | EUR 7.8B | EUR 9B |
| 2024 | EUR 44.3B | EUR 5.6B | EUR 5.9B |
| 2023 | EUR 41.1B | EUR 5.4B | EUR 8.6B |
| 2022 | EUR 40.3B | EUR 8.4B | EUR 8.3B |
| 2021 | EUR 39.2B | EUR 6.2B | EUR 8.5B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 9.5x | TTM | Native | EUR / EUR |
| 2024 | 20.5x | TTM | Native | EUR / EUR |
| 2023 | 20.8x | TTM | Native | EUR / EUR |
| 2022 | 13.5x | Annual | Native | EUR / EUR |
| 2021 | 17.8x | Annual | Native | EUR / EUR |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Underlying profit margins reflect powerful commercial pricing power driven by high-value specialty biologics. Gross margins expanded to 72.1% in 2025, demonstrating that complex medicines command premium prices across global healthcare systems. While reported operating margins temporarily dipped to 20.5% due to clinical write-downs and restructuring costs, core business profitability remained strong. Selling off lower-margin consumer lines structurally lifts future profit margins toward 28% to 30%. As blockbuster respiratory indications scale and the launch portfolio expands without requiring proportional overhead, operating leverage will naturally widen profit margins, generating massive cash flows to reinvest in the business and reward shareholders.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | EUR 9.6B | 20.5% | 16.7% |
| 2024 | EUR 14.5B | 32.6% | 12.6% |
| 2023 | EUR 13B | 31.6% | 13.1% |
| 2022 | EUR 13.1B | 32.6% | 20.8% |
| 2021 | EUR 8.1B | 20.7% | 15.9% |
Balance sheet and leverage
AI Review
The balance sheet stands as a financial fortress, offering immense security in a world of high interest rates. At the close of 2025, total equity stood at 71.4 billion euros against a conservative debt-to-equity ratio of 0.28, supported by strong interest coverage exceeding ten times earnings. The company faces virtually no borrowing distress. Strategic resilience expanded dramatically following the sale of a controlling stake in the consumer healthcare division, which delivered approximately 10 billion euros in net cash proceeds. This liquidity injection virtually eliminated net debt, giving leadership complete flexibility to fund multi-billion-euro share repurchases and selective biotech acquisitions without risking credit downgrades.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | EUR 20.3B | EUR 7.7B | EUR 12.9B net debt | 1.09x |
| 2024 | EUR 17.9B | EUR 7.9B | EUR 10.5B net debt | 1.46x |
| 2023 | EUR 18.4B | EUR 9B | EUR 9.7B net debt | 1.27x |
| 2022 | EUR 21.5B | EUR 12.7B | EUR 8.5B net debt | 1.42x |
| 2021 | EUR 22.5B | EUR 10.1B | EUR 12.3B net debt | 1.44x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management is demonstrating disciplined capital stewardship by shifting investment away from physical brick-and-mortar factories toward clinical scientific innovation. Physical capital expenditures accounted for just 3.8% of revenue in 2025, freeing up substantial cash flow. Instead of constructing unnecessary manufacturing plants, the company directs its capital firepower into research and development, which totaled 7.84 billion euros in 2025. This spending pattern reveals strict return-on-capital discipline under new executive leadership. Deciding to swiftly halt ineffective drug trials preserves capital rather than throwing good money after bad. Reallocating research budgets into high-conviction neurology and immunology candidates protects profit margins and focuses investment on durable, high-return medicines.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | EUR 1.8B | EUR 7.8B |
| 2024 | EUR 3.2B | EUR 7.4B |
| 2023 | EUR 1.6B | EUR 6.5B |
| 2022 | EUR 2.2B | EUR 6.5B |
| 2021 | EUR 2B | EUR 5.7B |
Quarterly Forecast Scenarios
Sanofi Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in EUR; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (EUR) | Base case (EUR) | Bull case (EUR) | S&P 500 benchmark (USD) | FX (EUR/USD) |
|---|---|---|---|---|---|
| €76.27 | €76.54 | €77.01 | $750.26 | 1.1360 | |
| €77.03 | €79.11 | €80.86 | $736.44 | 1.1255 | |
| €78.48 | €81.31 | €83.29 | $743.40 | 1.1272 | |
| €80.15 | €83.52 | €86.62 | $755.15 | 1.1312 | |
| €81.75 | €86.32 | €89.22 | $776.22 | 1.1401 | |
| €84.20 | €88.98 | €93.68 | $787.13 | 1.1452 | |
| €85.04 | €91.03 | €97.43 | $802.83 | 1.1510 | |
| €86.74 | €92.92 | €100.35 | $812.05 | 1.1584 | |
| €85.01 | €95.35 | €104.36 | $839.18 | 1.1617 | |
| €87.56 | €97.47 | €108.54 | $850.50 | 1.1694 | |
| €89.31 | €99.29 | €111.79 | $872.39 | 1.1719 | |
| €90.20 | €100.79 | €114.03 | $885.51 | 1.1763 | |
| €92.01 | €102.69 | €115.17 | $909.56 | 1.1781 | |
| €92.01 | €103.95 | €118.63 | $916.13 | 1.1832 | |
| €92.86 | €104.72 | €121.00 | $936.51 | 1.1867 | |
| €91.00 | €105.31 | €121.00 | $947.34 | 1.1894 | |
| €88.34 | €105.82 | €122.21 | $969.59 | 1.1887 | |
| €85.69 | €104.64 | €124.65 | $979.99 | 1.1913 | |
| €83.89 | €104.80 | €122.16 | $999.60 | 1.1971 | |
| €82.21 | €105.89 | €123.38 | $1,012 | 1.1964 |
Behind the synthesis
How each opinion shapes the consensus
Independent factual verification reveals a clear division across reports regarding pipeline reality. Multiple reports failed basic data freshness checks by treating amlitelimab in atopic dermatitis as an active late-stage asset, directly contradicting the confirmed July 24, 2026 regulatory withdrawal and accompanying 952-million-euro impairment. These obsolete submissions were heavily downweighted to prevent distorted terminal expectations. Conversely, reports grounded in primary regulatory filings, audited half-year results, and verified corporate disclosures receive dominant weighting. These establish that underlying operational momentum is strong: the flagship immunology franchise is accelerating through respiratory label expansions, specialty launches like hemophilia and RSV therapies are diversifying revenues, and the consumer health carve-out provides substantial liquidity for share retirements. The strongest credible contrarian insight recognizes that while near-term cash conversion is robust, the approaching March 2031 United States compound patent boundary imposes reverse operating leverage that strictly caps multiple expansion.
Universal Investor AI
The Polymath
GPT-6 AstraThis assessment earns high weighting by verifying continuing-operations accounting against SEC filings, recognizing the July 2026 amlitelimab termination, and distinguishing group revenue from shared Regeneron collaboration economics. Its modeling of compound patent expiration without assuming automatic cliff collapse provides an economically rigorous, highly grounded valuation anchor.
Universal Investor AI
The Polymath
Opus 5Weighted highly for forensic precision. It accurately details the Q2 2026 pipeline impairment, dissects the difference between IFRS and business EPS, and incorporates the Section 232 tariff shelter and MFN pricing dynamics. Its disciplined view on patent cliff multiple compression reflects superior factual grounding.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashAwarded substantial weight for sound owner-earnings discipline. It integrates the July 2026 clinical discontinuations, accurately examines specialty launch momentum in Altuviiio and Beyfortus, and establishes realistic discounted cash-flow boundaries without assuming multiple rerating into an impending patent expiration boundary.
Michael Burry AI
The Vulture
Gemini 3.8 FlashMerits meaningful weight for rigorous balance-sheet scrutiny and accurate recognition of the July 2026 non-cash impairment. It correctly captures the commercial acceleration of Altuviiio and Beyfortus, although its medium-term price targets rely on multiple expansion that somewhat discounts looming biosimilar litigation timelines.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashReceives moderate weight for accurately acknowledging the amlitelimab discontinuation and tracing Opella transaction liquidity into buybacks and late-stage neuroimmunology. While its multiple expansion assumptions are somewhat generous given looming patent boundaries, its analysis of Beyfortus adoption and non-cyclical biological demand is causally robust.
Universal Investor AI
The Polymath
Gemini 3.8 FlashSupported by solid verification of the amlitelimab write-down and thorough examination of non-Dupixent launches. It provides a unique, well-grounded insight into Regeneron collaboration loan extinguishment, though its medium-term valuation multiples are slightly optimistic relative to historical pharmaceutical de-risking cycles.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashEarns solid weighting for an accurate synthesis of executive governance, R&D triage, and Opella transaction dynamics. It properly notes the amlitelimab impairment and examines French sovereign industrial alignment, providing credible causal mechanics behind share repurchases and operating margin stabilization.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashGranted moderate weight for correctly incorporating the amlitelimab termination charge while accurately capturing Dupixent's chronic obstructive pulmonary disease volume acceleration. However, its aggressive valuation rerating to seventeen times earnings overstates institutional appetite ahead of the 2031 loss-of-exclusivity window.
Elon Musk AI
The Visionary
Gemini 3.8 FlashReceives modest weighting. It correctly identifies the amlitelimab impairment and Altuviiio launch traction, while soundly evaluating how Opella liquidity buffers share count compression. However, its bull-case assumptions regarding frontier synthetic biology displacement and long-range multiple expansion lack near-term empirical grounding.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashDownweighted primarily due to factual pipeline obsolescence, treating amlitelimab Phase 3 data in eczema as an active catalyst while missing the July 2026 abandonment. However, its analysis of sovereign balance sheet health, Opella liquidity deployment, and late-cycle macroeconomic defensiveness offers modest contextual value.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashDownweighted due to internal contradictions and pipeline inaccuracies. The report treats amlitelimab as an ongoing Phase 3 pipeline asset in risk modeling, overlooking the July 2026 termination. While its cash conversion and dividend coverage frameworks are sound, the clinical premise error weakens its forward forecasts.
Universal Investor AI
The Polymath
Gemini 3.8 FlashHeavily downweighted due to stale clinical premises. The report projects Phase 3 approval and commercialization for amlitelimab in atopic dermatitis, completely ignoring Sanofi's official July 24, 2026 discontinuation and subsequent impairment charge. Unverified cash-flow yields and unadjusted multiples further diminish its analytical utility.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashAssigned minimal weight because it relies on outdated pipeline assumptions. It models amlitelimab Phase 3 clinical de-risking and FDA approval as primary growth drivers, directly contradicting the confirmed July 2026 program cancellation. This core factual error undermines its projected operating margin trajectory and earnings forecasts.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashAssigned minimal weight due to critical factual inconsistencies. Despite noting executive turnover, it heavily bases its bull scenario and timeseries trajectory on amlitelimab Phase 3 atopic dermatitis registration and launch, completely ignoring the program's verified July 2026 discontinuation and impairment.
Research Provenance
References & Context
This Sanofi consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 99 deduplicated sources retained for this batch.
- 01regn-20251231sec.gov
- 02Sanofi - Form 6-K - FY2026sec.gov
- 03sny-20251231sec.gov
- 04sny-20260630_d2sec.gov
- 05www.sec.govsec.gov
- 06SANOFI PRESS RELEASE Q2 2026 1 Press Releasesanofi.com
- 07Sanofi drug pipeline worries, Dupixent dependence shake shares | 95 KQDS95kqds.com
- 08Sanofi outlook and pipeline, shares steady as analysts track Dupixent growthad-hoc-news.de
- 09Sanofi stock holds steady as analysts see upside from asthma pipelinead-hoc-news.de
- 10Trump Administration Announces Section 232 Tariffs on Pharmaceuticals | Brownsteinbhfs.com
- 11RBC Capital initiates Sanofi stock at Sector Perform on transition risks By Investing.comca.investing.com
- 12U.S. Pharma Tariffs And MFN Become Law After April 2 Updateclinicalleader.com
- 13A New Round in US Pharma Tariffs: What's at Play? - DCAT Value Chain Insightsdcatvci.org
- 14With Dupixent driving growth, Sanofi touts 'vigorous defense' to extend US exclusivityfiercepharma.com
- 15JPM26: Sanofi demonstrates significant strategic progress with several novel drugsfinance.yahoo.com
And 84 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: EUR, USD (quote EUR; primary reporting EUR; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.